Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases, announced today it will not accelerate the expiry of the private placement warrants that were issued on April 29, 2009 with a $1.00 exercise price.
The company is giving notice to the holders advising that the expiry date will remain April 29, 2011 and will not be accelerated to January 19, 2010. All other terms of these warrants remain unchanged, including the right of the company to accelerate on occurrence of a subsequent trigger event in accordance with the terms of the warrants.
Nomic® and Parker Institute for Cancer Immunotherapy (PICI) launch large-scale protein profiling to investigate immunotherapy responses in RADIOHEAD study